Skip to main content

Retacrit and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with Retacrit (epoetin alfa).

Major

High Blood Pressure (Hypertension)

Major Potential Hazard, High plausibility

erythropoiesis-stimulating agents - hypertension

The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension. These agents may cause blood pressure to rise. Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents. Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment. Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing. It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.

References

  1. Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991): 84-6
  2. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989): 992-1000
  3. Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988): 97-100
  4. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990): 947-55
  5. "Product Information. Epogen (epoetin alfa)." Amgen PROD (2002):
  6. "Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc PROD (2002):
  7. Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994): s36-43
  8. "Product Information. Aranesp (darbepoetin alfa)." Amgen (2001):
  9. "Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT (2007):
View all 9 references

Retacrit drug interactions

There are 21 drug interactions with Retacrit (epoetin alfa).

Retacrit disease interactions

There are 5 disease interactions with Retacrit (epoetin alfa) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer